These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 23561229

  • 1. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.
    Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg WM.
    J Clin Psychiatry; 2013 Mar; 74(3):242-8. PubMed ID: 23561229
    [Abstract] [Full Text] [Related]

  • 2. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
    Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV.
    J Clin Psychopharmacol; 2014 Feb; 34(1):47-56. PubMed ID: 24172209
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
    Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D.
    J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
    [Abstract] [Full Text] [Related]

  • 4. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.
    Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg WM, Liebowitz M, Khan A.
    J Psychiatry Neurosci; 2014 Jan; 39(1):40-9. PubMed ID: 24144196
    [Abstract] [Full Text] [Related]

  • 5. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP, Gourion D, Montagne A, Rostin M, Poirier MF.
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [Abstract] [Full Text] [Related]

  • 6. The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.
    Montgomery SA, Mansuy L, Ruth AC, Li D, Gommoll C.
    Int Clin Psychopharmacol; 2014 Jan; 29(1):26-35. PubMed ID: 24172160
    [Abstract] [Full Text] [Related]

  • 7. Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7-17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies.
    Radecki DT, Robieson WZ, Gopalkrishnan M, Greenberg E, Aziz M.
    J Child Adolesc Psychopharmacol; 2024 Jun; 34(5):241-250. PubMed ID: 38700708
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.
    Sambunaris A, Gommoll C, Chen C, Greenberg WM.
    Int Clin Psychopharmacol; 2014 Jul; 29(4):197-205. PubMed ID: 24667487
    [Abstract] [Full Text] [Related]

  • 9. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder.
    Gommoll CP, Greenberg WM, Chen C.
    J Drug Assess; 2014 Jul; 3(1):10-9. PubMed ID: 27536449
    [Abstract] [Full Text] [Related]

  • 10. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
    Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, Reed CR.
    J Clin Psychiatry; 2011 Apr; 72(4):441-7. PubMed ID: 21527122
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.
    Blum SI, Tourkodimitris S, Ruth A.
    J Affect Disord; 2015 Jan 01; 170():230-6. PubMed ID: 25259674
    [Abstract] [Full Text] [Related]

  • 12. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L.
    Int J Clin Pract; 2013 Nov 01; 67(11):1089-104. PubMed ID: 24016209
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Croft HA, Pomara N, Gommoll C, Chen D, Nunez R, Mathews M.
    J Clin Psychiatry; 2014 Nov 01; 75(11):e1291-8. PubMed ID: 25470094
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
    Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME.
    J Clin Psychiatry; 2012 Jul 01; 73(7):953-9. PubMed ID: 22901346
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.
    J Clin Psychiatry; 2004 Oct 01; 65(10):1356-64. PubMed ID: 15491239
    [Abstract] [Full Text] [Related]

  • 16. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
    Jacobsen PL, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH.
    J Clin Psychiatry; 2015 May 01; 76(5):575-82. PubMed ID: 26035185
    [Abstract] [Full Text] [Related]

  • 17. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun 01; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 18. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.
    Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M.
    J Clin Psychiatry; 2009 Apr 01; 70(4):526-39. PubMed ID: 19358790
    [Abstract] [Full Text] [Related]

  • 19. The effects of levomilnacipran ER in adult patients with first-episode, highly recurrent, or chronic MDD.
    Kornstein SG, Gommoll C, Chen C, Kramer K.
    J Affect Disord; 2016 Mar 15; 193():137-43. PubMed ID: 26773906
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.